VivaTech 2019: Thales Receives Global Innovator Award and Invites Visitors to Be Astronauts for a Day
7.5.2019 08:00:00 EEST | Business Wire | Press release
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005645/en/
"Thales Alenia Space". Copyright: Thales
Global recognition for research and innovation
The Derwent Top 100 Global Innovators ranking recognises the volume, success and influence of the patents filed by technology companies. Thales has appeared six times in this prestigious ranking, reflecting the company’s commitment to innovating, bringing inventions to market and protecting its ideas.
This distinction comes at a turning point in Thales’s history. With the completion of the acquisition of Gemalto on 2 April, the Group now employs 28,000 engineers, devotes €1 billion a year to self-funded R&D and maintains a portfolio of 20,500 patents, including 400 filed in 2018. At the show, Thales will also sign the LGBT+ Charter championed by Autre Cercle, thus highlighting the group’s strategy of promoting diversity and inclusion across its talent pool, as a way to free creative potential and foster innovation.
Thales at VivaTech: AI for every decisive moment
Thales will be showcasing its latest innovations alongside some 30 start-ups from six countries specialising in artificial intelligence, connectivity, drone technology, cybersecurity and robotics.
A series of demonstrations will show how advanced technology helps real-life users to understand the most complex situations:
- Columbus invites visitors to feel what it’s like to be an astronaut on-board the International Space Station’s science laboratory.
- The autonomous train demonstrator lets visitors drive a New York City subway train and see how they match up to the capabilities of artificial intelligence.
- Piume allows users to experience what it’s like to be an explorer or a researcher working in harsh environments.
- Geonav uses the Galileo satellite constellation to prevent risks faced by high-level athletes, without the dropped signals that often occur inside sports stadiums.
- Smart New World combines the power of holographic displays with IoT (Internet of Things) technology.
- The 3D interactive hologram table developed with the Australian start up Euclideon models anything you can imagine: cities, objects, design techniques and much more.
Thales experts will also be taking part in around 40 panel sessions to discuss how artificial intelligence that is trustable, explainable and certifiable can be used to invent or reinvent the cities of the future, develop autonomous trains and future medical imaging solutions, protect the environment and take space exploration to the next frontier. The schedule for the demonstrations and panel sessions can be found on the Thales event website.
Thales Decisive Journeys at VivaTech
- DecisiveJourney#1: From space observation to personal data protection: find out how trusted AI is a decisive technology for Thales
- DecisiveJourney#2: Thales technologies applied to environmental protection
- DecisiveJourney#3: Artificial nano-neurons and medical imaging: Thales innovations reshaping the future of medicine
- DecisiveJourney#4: How to develop responsible AI
- DecisiveJourney#5: How digital is changing our companies and work methods
About Thales
The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018
PLEASE VISIT
Thales
Group
Twitter: @Thalesgroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005645/en/
Contact information
Thales, Media Relations
Alice Pruvot +33 (0)7 70 27 11 37
alice.pruvot@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom